NCI-Penn Collaboration Finds Targeted Immune Cells Shrink Tumors in Mice

February 11, 2009

PHILADELPHIA - Researchers have generated altered immune cells that are able to shrink, and in some cases eradicate, large tumors in mice. The immune cells target mesothelin, a protein that is highly expressed, or translated in large amounts from the mesothelin gene, on the surface of several types of cancer cells. The approach, developed by researchers at the University of Pennsylvania School of Medicine and the National Cancer Institute (NCI), shows promise in the development of immunotherapies for certain tumors. The study appears online this week in the Proceedings of the National Academy of Sciences.

Expression of mesothelin is normally limited to the cells that make up the protective lining (mesothelium) of the body's cavities and internal organs. However, the protein is abundantly expressed by nearly all pancreatic cancers and mesotheliomas and by many ovarian and non-small-cell lung cancers. Although the biological function of mesothelin is not known for certain, it is thought to play a role in the growth and metastatic spread of the cancers that express it.

"Since tumor cells are derived from the body's normal cells, the immune system often does not recognize tumor molecules as dangerous or foreign and does not mount a strong attack against them," said Ira Pastan, M.D., chief of the Laboratory of Molecular Biology in NCI's Center for Cancer Research, a study collaborator. Moreover, even though it is possible to genetically engineer immune system cells to recognize molecules on tumor cells, most of the molecules found on tumor cells are also found on normal cells. But, Pastan notes, "Mesothelin is a promising candidate for generating tumor-targeting T cells, given its limited expression in normal tissues and high expression in several cancers."

Previous laboratory research has shown that certain immune system cells, called T cells, can kill tumor cells that express mesothelin. In addition, studies in both animals and humans have shown that antibodies directed against mesothelin protein can shrink tumors.

In the new study, the research team genetically engineered human T cells to target human mesothelin. To produce them, a modified virus was used as a delivery vehicle, or vector, to transfer synthetic genes to T cells. These genes directed the production of hybrid, or chimeric, proteins that can recognize and bind to mesothelin and consequently stimulate the proliferation and cell-killing activity of the T cells. In laboratory studies, the team found that the engineered T cells proliferated and secreted multiple cytokines when exposed to mesothelin. Cytokines are proteins that help control immune functions. The cells also expressed proteins that made them resistant to the toxic effects of tumors and their surrounding tissues.

To study the effects of the engineered T cells on tumor tissue, the researchers implanted human mesothelioma cells underneath the skin of mice. About six weeks later, when tumors had formed and progressed to an advanced stage, the engineered T cells were administered to the mice. Direct injection of the T cells into tumors or into veins of the mice resulted in disappearance or shrinkage of the tumor.

"Based on the size of the tumors and the number of cells administered, we estimate that one mesothelin-targeted T cell was able to kill about 40 tumor cells," said study leader Carl H. June, M.D., Professor of Pathology and Laboratory Medicine and director of Translational Research at Penn's Abramson Cancer Center. "This finding indicates that small doses of these cells may have potential in treating patients with large tumors. Clinical trials are being developed to investigate this approach in patients with mesothelioma and ovarian cancer."

The University of Pennsylvania Health System

---

---

	Advances in Clinical Chemistry, Volume 57 by Gregory Makowski (Series Editor) Volume 53 in the internationally acclaimed Advances in Clinical Chemistry contains chapters submitted from leading experts from academia and clinical laboratory science. Authors are from a diverse field of clinical chemistry disciplines and diagnostics, ranging from basic biochemical exploration to cutting-edge microarray technology.Leading experts from academia and clinical laboratory science Volume emphasizes novel laboratory advances with application to clinical laboratory diagnostics and practical basic science studies
	Cancer Vaccines (Annals of the New York Academy of Sciences) by Ralph M. Steinman (Editor), Kenichiro Hasumi (Editor), Olivera J. Finn (Editor), Jacques Banchereau (Editor) With ten million persons afflicted each year, no one is entirely immune to cancer and its devastating effects on individuals and families. But recent advances in the development of cancer vaccines—either as therapeutic agents or as preventative measures—are hopeful indicators of progress in this field. This volume comprises invited chapters from world-renowned researchers and clinicians that shed light on recent steps forward in immunotherapeutic and preventive approaches for future cancer vaccines.NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas.ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order...
	Malignant Mesothelioma (Recent Results in Cancer Research) by Andrea Tannapfel (Editor) Malignant mesothelioma is an aggressive and fatal neoplasm of serous membranes that still shows a rising incidence worldwide. This book covers all the important aspects of the disease by bringing together contributions from selected experts in the fields of epidemiology, imaging, pathological diagnosis, therapy, genetics, and screening. Special emphasis is placed on the latest diagnostic techniques and current therapy standards. In addition, the mineralogy of asbestos is reviewed and clear advice is included on the analysis of tissue mineral fiber content. By providing a compact, scientifically based, and up-to-date overview of the management of malignant mesothelioma, this volume will be invaluable for all clinicians and pathologists who are engaged in the diagnosis and treatment of the...
	Methods of Cancer Diagnosis, Therapy, and Prognosis: Ovarian Cancer, Renal Cancer, Urogenitary tract Cancer, Urinary Bladder Cancer, Cervical Uterine ... Leukemia, Multiple Myeloma and Sarcoma by M. A. Hayat (Editor) This sixth volume in the series Methods of Cancer Diagnosis, Therapy, and Prognosis discusses Ovarian Cancer, Renal Cancer, Urogenitary Cancer, Urinary Bladder Cancer, Cervical Uterine Cancer, Skin Cancer, Leukemia, Multiple Myeloma and Sarcoma. Both standard and emerging therapies for these cancers, written by expert oncologists/pathologists in this field, are included. This fully illustrated volume Identifies biomarkers based on genetic alterations for clear cell ovarian adenocarcinoma. Identifies subgroups of ovarian cancer by using differential gene expression. Includes the application of the power-Doppler imaging for distinguishing benign from malignant complex adrenal masses in ovarian cancer. Emphasizes the advantage of using cytoreduction surgery for diagnosing advanced ovarian...
	Ovarian Cancer: State of the Art and Future Directions in Translational Research (Advances in Experimental Medicine and Biology) by George Coukos (Editor), Andrew Berchuck (Editor), Robert Ozols (Editor) Aegean Conferences is an independent, nonprofit, educational organization directed and managed by the scientific community. The board is made up of nine researchers/scientists in various disciplines from Harvard, Brown, University of Pennsylvania, UCSD, Princeton, Biovista and the Foundation for Biomedical Research Academy of Athens. The board both invites and approves unsolicited proposals for Conferences in all fields of Science, Engineering, Arts, and Humanities. The purpose of the Conferences is to bring together individuals with common interests to examine the emerging and most advanced aspects of their particular field. The Symposium on Ovarian Cancer: State of the Art and Future Directions intends to bring together international experts interested in the development of novel...
	Pancreatic Cytopathology (Essentials in Cytopathology) by David C. Chhieng (Author), Edward B. Stelow (Author), M.W. Stanley (Foreword) Designed to be concise and easy to use, this volume focuses on pancreas cytopathology. It is the ideal companion for practitioners on the move. It is published in the Essentials in Cytopathology book series and fulfills the need for an easy-to-use and authoritative synopsis of site specific topics in cytopathology. These guide books fit into the lab coat pocket, ideal for portability and quick reference. Each volume is heavily illustrated with a full color art program, while the text follows a user-friendly outline format.
	Serous Effusions: Etiology, Diagnosis, Prognosis and Therapy by Ben Davidson (Editor), Pinar Firat (Editor), Claire W. Michael (Editor) Serous (peritoneal, pleural and pericardial) effusions are a frequently encountered clinical finding in everyday medical practice and one of the most common specimen types submitted for cytological evaluation. The correct diagnosis of effusions is critical for patient management, as well as for prognostication and yet many clinicians find diagnosis and treatment of cancer cells in effusions very challenging. Featuring multiple microscopic illustrations of all diagnostic entities and ancillary techniques (immunhistochemistry and molecular methods), this book provides a comprehensive, authoritative guide to all aspects of serous effusions, including etiology, morphology and ancillary diagnostic methods, as well as data related to therapeutic approaches and prognostication. Section one...
	Pathology of Malignant Mesothelioma by Francoise Galateau-Sallé (Editor) • Only up-to-date title in the market • Current topic with significant media coverage • Internationally relevant, the use of asbestos and its consequences is a global problem • This title aids in pathological diagnosis which is very difficult • Contributors are experts from France, UK, USA, Australia and Canada • Plentiful, colored illustrations complete the text • Target group exceeds pathologists: The diagnosis is evidence for medico-legal purposes, which makes the book invaluable to members of legal profession specializing in this disease
	Effusion Cytology: A Practical Guide to Cancer Diagnosis by Parvin Ganjei-Azar MD (Author), Merce Jorda PhD (Author), Awtar Krishan PhD (Author) Today, cytology of body cavity fluids is an integral part of cancer staging. A positive diagnosis indicates a high-stage (III or IV) cancer in a majority of instances. General pathologists and cytotechnologists rely on routine cytomorphologic criteria to help oncologists in their staging of cancer patients. The diagnostic clarity, however, is challenged by many false negatives and occasional false positive results. The former is usually followed by an unnecessary surgical procedure in the case of an under-staged cancer and the latter may prevent treatment of a potentially curable disease due to a falsely up-staged cancer. Effusion Cytology is a practical manual in diagnosis and interpretation of body cavity fluid (BCF) specimens. This highly illustrated volume will provide handy...
	Lung Cancer Therapy Annual 6 (v. 6) by Heine H. Hansen (Editor) Oncology research and practice in lung cancer continues to develop rapidly. This latest edition of Lung Cancer Therapy Annual briefs the oncology community with a review of the recent literature, emphasizing the therapeutic aspects. It offers an update of the impact that this information will have on the day-to-day management of the lung cancer patient. New to the Sixth Edition: new information on approaches to the management of lung cancer the emerging role of "targeted therapy" with small molecules an update on the use of adjuvant therapy in addition to surgery Additional topics include: epidemiology recent advances in the pharmacogenetics of non-small cell lung cancer prevention, early detection, and screening histopathology staging, staging procedures, and...